Surgical Site Infection Clinical Trial
Official title:
Do Intra-incisional Subdermal Antibiotics Alter the Colony Count of P. Acnes
The specific outcome is to determine whether the colony count of Propionibacterium acnes, one of the commonest causes of shoulder infection and not eradicated by conventional forms of surgical preparatory solutions and antibiotics, in a shoulder surgical wound will be altered by the use of subdermal cefazolin.
Purpose The purpose of the study is to review if the subdermal injection of antibiotics
intraoperatively reduces the bacterial load in the subcutaneous tissue during the course of
an open shoulder operation.
Null Hypothesis There will be no change in the colony count of P.acnes following
administration of subdermal antibiotics.
Justification. P. Acnes is the most common cause of shoulder infection. The incidence of
post-operative shoulder joint infection varies from 4-18%. The P.acnes organism is a Gram
positive, largely anaerobic but aerotolerant commensal of the deep skin follicles and
standard skin preparation may inadequately penetrate the pilosebaceous follicles. It has also
been shown in a study by Levy et al that 41.8% of patients had a positive biopsy or aspirate
result for P.acnes prior to implantation of components. This study will determine whether
intraoperative subdermal antibiotic administration reduces the bacterial load and in turn
reduce the incidence of shoulder joint infection. Cefazolin has been chosen because
cephalosporins and penicillins have the lowest minimum inhibitory concentration (MIC) against
P.acnes. There is a lower incidence of allergy to cephalosporins than penicillins. This study
has the potential to change clinical practice world wide.
Objectives The specific outcome is to compare the bacterial cell count on either side of a
surgical wound and determine if subcutaneous antibiotics on a single side reduces
subcutaneous cell counts over various time courses throughout the operation.
Research Method. Targeted recruitment is 20 patients in this pilot study. This figure has
been arrived at after determining the power of the study, significance levels and the
anticipated drop in P.acnes count colonisation after the use of local antibiotics. It is also
a number that can be achieved rapidly, enabling us to assess whether there is an observed
difference between the groups and thereby gauge the feasibility of a larger trial.
The patients will receive the standard of care pre-operative antibiotics 30 minutes prior to
incision and surgical intervention. The skin will also be prepped using a chlorhexidine
alcohol based solution as is standard at the investigator's institution. The investigators
will divide the normal surgical incision into three even sections on either side of the
incision, thus forming six segments. One side of the wound will be injected with three
aliquots of 3 mLs using a concentration 100mg/mL of cefazolin. This equates to 900mg of
subcutaneous cefazolin antibiotic. There are no specific efficacy criteria for agents in this
setting that have been standardised and approved by an official oversight agency. We have
selected this quantity based upon safe and wide-spread use of this concentration in a
systemic manner as well as being mindful of the readily available concentrations. There is no
known study describing any harm on introduction of antibiotics into the soft tissue, e.g.
vancomycin used topically in prosthetic joints as a prophylaxis against infection, and the
widespread use of intra-muscular (IM) penicillin products. Subcutaneous cefazolin has been
demonstrated as safe in a porcine model while delivering higher cutaneous concentrations than
with comparative systemic administration. Subcutaneous ceftriaxone is approved for use in
France and is of increasing use for geriatric populations as well as by infectious disease
practitioners. There is published evidence of safe administration of cefazolin in tumescent
anesthesia antibiotic delivery mixed with lidocaine, epinephrine, and sodium bicarbonate.
Standardized samples from all six sections will be sampled using a disposable 6mm Mitex
biopsy punch before inoculation and this process will be repeated at the 60 minute mark. The
samples will be sent to the microbiology lab where colony count will be obtained and long
term cultures i.e. 3 weeks will be performed.
It is routine in surgery to inject subcutaneous substances and not infrequently biopsies are
taken. The only potential side effect is allergy to cephalosporins, which would have been
determined preoperatively and is part of the exclusion criteria. There will be no expected
increased incidence of infection or bleeding.
Collection, Handling and Storage Specimens will be labeled with appropriate patient
identifiers and clearly labeled as to the site of collection, and sent to the laboratory
immediately for processing as soon as possible. Tissue biopsies will be sent either in
anaerobic transport media or in a sterile container with a piece of sterile gauze moistened
with non-bacteriostatic saline, or if piece is large enough, just a few drops of
non-bacteriostatic in the container to prevent the tissue from desiccation.
Tissue Processing All specimen manipulations will be carried out in the Biological Safety
Cabinet and processed as soon as possible. Tissues will be inoculated to media to maximize
the recovery of Propionibacterium acnes which will include a 5% sheep's blood agar and
chocolate agar plates and thioglycollate (THIO) broth incubated under 5% carbon dioxide (CO2)
at 35 Celsius. Brucella and Columbia Naladixic acid (CNA) agars will be incubated in an
anaerobic conditions at 35 Celsius.
With sterile forceps, the tissue will be transferred to a sterile Petri plate. Using a
disposable sterile scalpel the tissue will be chopped into enough small pieces to inoculate
all the media required. Several pieces of tissue will be added to THIO broth. The remaining
media will be inoculated if order of least selective to the most selective: the blood agar
plate, chocolate agar plate, Brucella and CNA agar.
Lastly "touch preps" for the gram smears will be performed by gently touching a fresh piece
of tissue onto the microscope slides. This piece of tissue will be discarded as it now is
potentially contaminated.
Tissue Investigation
All media will be incubated for 5 days and read daily. The broth will be held for 21 days and
examined at 7, 14 and 21 days after the initial 5 day reads. There is no need to follow the
patients up for 2 years as we are only looking to determine change in intra operative colony
counts which can be determined within 21 days and may be linked to a reduction in infection.
All bacterial growth will be investigated per usual laboratory procedures for identification
and antimicrobial susceptibility testing.
Results will be reported to the study investigators in a timely fashion
Statistical Analysis. Samples will be compared with either side of the wound over the
respective time periods. Count averages will be obtained and analysised using a paired
t-test.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04096885 -
The Inselspital Surgical Cohort Study
|
||
Terminated |
NCT03820648 -
Wound Protector Dual-ring Alexis® in Pancreaticoduodenectomy
|
N/A | |
Completed |
NCT04067843 -
Effect of Photodynamic Treatment on Skin Microbiome. Single Center Study
|
N/A | |
Terminated |
NCT04042077 -
Delafloxacin IV and OS Administration Compared to Best Available Therapy in Patients With Surgical Site Infections
|
Phase 3 | |
Completed |
NCT05841576 -
Anaesthetic Management Guided by COMET Measurements
|
N/A | |
Withdrawn |
NCT05338281 -
NPWT for Abdominal Incisions in DIEP Reconstructions: A RCT
|
N/A | |
Recruiting |
NCT03042091 -
Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery
|
Early Phase 1 | |
Completed |
NCT01697748 -
Prospective Study on Cesarean Wound Outcomes
|
N/A | |
Terminated |
NCT01789697 -
Text Message Study
|
N/A | |
Recruiting |
NCT05966961 -
Novosyn® CHD vs Polyglactin 910 Suture to Close Wounds After Emergency or Elective Laparotomy or Laparoscopic Surgery
|
||
Recruiting |
NCT05077592 -
Addition of Pre-wound Closure Povidone Iodine Wash Versus Direct Wound Closure Effect on Surgical Site Infections
|
Phase 4 | |
Recruiting |
NCT05502380 -
Broad-spectrum Antibiotic Prophylaxis in Tumor and Infected Orthopedic Surgery
|
Phase 3 | |
Recruiting |
NCT05763602 -
PVI to Prevent S. Aureus SSI After Fixation of HELEF (POTENT Study)
|
Phase 4 | |
Recruiting |
NCT03221023 -
Intrawound Vancomycin Prophylaxis for Neural Stimulator
|
Phase 2/Phase 3 | |
Completed |
NCT03257202 -
Topical Treatment and Prevalence of P. Acnes
|
Phase 2 | |
Completed |
NCT06154720 -
Surgical Site Infection After Episiotomy Repair Related to Routine Use of Antibiotic Prophylaxis in Low-Risk Population
|
||
Not yet recruiting |
NCT06465901 -
A Stratified, Multi-ARm, muLti-site Randomised Platform Trial Aiming to Reduce the INcidence of Post-operative SSI
|
N/A | |
Not yet recruiting |
NCT04820075 -
Efficacy of an Intervention to Improve the Preoperative Shower in Scheduled Surgery
|
N/A | |
Recruiting |
NCT03561376 -
Zinc Oxide Versus Petrolatum Following Skin Surgery
|
Early Phase 1 | |
Not yet recruiting |
NCT04496180 -
Prevena to Prevent Surgical Site Infection After Emergency Abdominal Laparotomy
|
N/A |